Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study
Objective This study assessed patient‐reported outcomes (PROs) in individuals with persistently positive antiphospholipid antibodies (aPL) to better understand how living with aPL may affect their quality of life. Methods Patients completed Patient‐Reported Outcomes Measurement Information System Ph...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11512 |
| _version_ | 1828065284747952128 |
|---|---|
| author | Julia K. Weiner Tristin Smith Claire K. Hoy Cyrus Sarosh Jacqueline A. Madison Amala Ambati Ajay Tambralli Noah Peters Corinne Packel Kelsey Gockman Yu Zuo Emily M. Briceño Vivek Nagaraja Jason S. Knight |
| author_facet | Julia K. Weiner Tristin Smith Claire K. Hoy Cyrus Sarosh Jacqueline A. Madison Amala Ambati Ajay Tambralli Noah Peters Corinne Packel Kelsey Gockman Yu Zuo Emily M. Briceño Vivek Nagaraja Jason S. Knight |
| author_sort | Julia K. Weiner |
| collection | DOAJ |
| description | Objective This study assessed patient‐reported outcomes (PROs) in individuals with persistently positive antiphospholipid antibodies (aPL) to better understand how living with aPL may affect their quality of life. Methods Patients completed Patient‐Reported Outcomes Measurement Information System Physical Function (PF) and Cognitive Function (CF) Short Forms as well as the pain intensity (PI) rating (scale of 1‐10). Patients were characterized for demographics, clinical manifestations of antiphospholipid syndrome (APS), cardiovascular risk factors, laboratory test results, and medication usage. Multivariate modeling was done via linear regression. Results Of 139 patients, 89 had primary APS, 21 had secondary APS, and 29 had persistent aPL without meeting clinical criteria for APS. The average T scores (±SD) for PF and CF were 45.4 ± 9.2 and 48.6 ± 11.6, respectively; the average for PI was 3.0 ± 2.6. Approximately half of the patients (47%) endorsed at least mild impairment in PF (T score < 45). Mean PF, CF, and PI did not differ between diagnostic groups. Individuals who endorsed more impairment on one measure also tended to endorse more impairment on another (Pearson r = 0.43‐0.59). In the multivariate models, age, smoking, pain medications, and serotonergic medications were associated with impairment in at least one PRO domain. The Damage Index for APS was significantly correlated with both PF and CF. Conclusion Individuals living with APS endorsed more impairment in PF (and potentially CF) than expected for the general population. The relationship between certain medications and PROs warrants further study, as does the longitudinal trajectory of these and other PROs. |
| first_indexed | 2024-04-10T23:11:25Z |
| format | Article |
| id | doaj.art-afbc614d5f5c4be4be20f4182afb0293 |
| institution | Directory Open Access Journal |
| issn | 2578-5745 |
| language | English |
| last_indexed | 2024-04-10T23:11:25Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj.art-afbc614d5f5c4be4be20f4182afb02932023-01-13T05:31:29ZengWileyACR Open Rheumatology2578-57452023-01-0151283710.1002/acr2.11512Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional StudyJulia K. Weiner0Tristin Smith1Claire K. Hoy2Cyrus Sarosh3Jacqueline A. Madison4Amala Ambati5Ajay Tambralli6Noah Peters7Corinne Packel8Kelsey Gockman9Yu Zuo10Emily M. Briceño11Vivek Nagaraja12Jason S. Knight13University of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan Ann Arbor MichiganUniversity of Michigan, Ann Arbor, and Mayo Clinic Scottsdale ArizonaUniversity of Michigan Ann Arbor MichiganObjective This study assessed patient‐reported outcomes (PROs) in individuals with persistently positive antiphospholipid antibodies (aPL) to better understand how living with aPL may affect their quality of life. Methods Patients completed Patient‐Reported Outcomes Measurement Information System Physical Function (PF) and Cognitive Function (CF) Short Forms as well as the pain intensity (PI) rating (scale of 1‐10). Patients were characterized for demographics, clinical manifestations of antiphospholipid syndrome (APS), cardiovascular risk factors, laboratory test results, and medication usage. Multivariate modeling was done via linear regression. Results Of 139 patients, 89 had primary APS, 21 had secondary APS, and 29 had persistent aPL without meeting clinical criteria for APS. The average T scores (±SD) for PF and CF were 45.4 ± 9.2 and 48.6 ± 11.6, respectively; the average for PI was 3.0 ± 2.6. Approximately half of the patients (47%) endorsed at least mild impairment in PF (T score < 45). Mean PF, CF, and PI did not differ between diagnostic groups. Individuals who endorsed more impairment on one measure also tended to endorse more impairment on another (Pearson r = 0.43‐0.59). In the multivariate models, age, smoking, pain medications, and serotonergic medications were associated with impairment in at least one PRO domain. The Damage Index for APS was significantly correlated with both PF and CF. Conclusion Individuals living with APS endorsed more impairment in PF (and potentially CF) than expected for the general population. The relationship between certain medications and PROs warrants further study, as does the longitudinal trajectory of these and other PROs.https://doi.org/10.1002/acr2.11512 |
| spellingShingle | Julia K. Weiner Tristin Smith Claire K. Hoy Cyrus Sarosh Jacqueline A. Madison Amala Ambati Ajay Tambralli Noah Peters Corinne Packel Kelsey Gockman Yu Zuo Emily M. Briceño Vivek Nagaraja Jason S. Knight Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study ACR Open Rheumatology |
| title | Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study |
| title_full | Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study |
| title_fullStr | Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study |
| title_full_unstemmed | Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study |
| title_short | Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study |
| title_sort | predictors and interrelationship of patient reported outcomes in antiphospholipid syndrome a cross sectional study |
| url | https://doi.org/10.1002/acr2.11512 |
| work_keys_str_mv | AT juliakweiner predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT tristinsmith predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT clairekhoy predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT cyrussarosh predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT jacquelineamadison predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT amalaambati predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT ajaytambralli predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT noahpeters predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT corinnepackel predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT kelseygockman predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT yuzuo predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT emilymbriceno predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT viveknagaraja predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy AT jasonsknight predictorsandinterrelationshipofpatientreportedoutcomesinantiphospholipidsyndromeacrosssectionalstudy |